Ticalicibart is a humanized IgG4kappa monoclonal antibody inhibitor targeting PCSK9. Ticalicibart has anti-hyperlipidaemic activity. Ticalicibart can be used for cardiovascular disease like hypercholesterolaemia research[1][2].
Purity:
99.028
CAS Number:
[3033317-31-3]
Target:
PCSK9
Application Notes:
MCE Product type: Inhibitory Antibodies
* VAT and and shipping costs not included. Errors and price changes excepted